Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab Combined with Docetaxel in mCRPC
NCT05156905Phase 1Terminated
- Sponsor
- University of California, San Diego
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cirmtuzumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, San Diego. Primary endpoint: Recommended Phase 2 Dose at 36 months. Started Jun 2022; status: terminated.
02
Drugs
cirmtuzumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05156905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156905.